Transcription of 1回 医薬品開発協議会 - 首相官邸ホームページ
1 1 1 2020 10 27 2 DX* PMDA DX *DX: Digital transformation3 / *RWD/RWE MID-NET NDB COVID-19 AMR * DDS AI ( ) AI post LINC , 2000 *( ) * BCRET AI CDMO/CMO * **: GAPFREE ACT-M/MS AMED CiCLE 4 - - ,3 ,10 ,8 PfizerJohnson & JohnsonMerck&CoAbbvieAmgenGileadBMSR ocheNovartisSanofiGSKAZB ayerNovoShireBIAlIerganMerck KGaAUCBS ervier evaluatepharma 20 $45,302$44,552$43,481$38,810$37,353$35,1 21$32,083$30,645$22,533$21,677$21,581$20 ,671$18,221$17,726$17,379$14,993$14,834$ 14.
2 700 45% 7% 44% 4% 2002 2019 2020 (Pfizer 2020 2019 30 2018 Lilly$19,580 Celgene$15,238 MylanBiogen 6 15 1 3 1 15 21 75 652,336 9 17 1 2 3 7 3 5 2 3 1/8,698 1/31,064 >>>>>>>>>> 7 024681012141990 1995 2000 2005 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 % 5 DATA BOOK2019 8 1 9 50,000 100,000 150,000 200,000 250,000 300,000 350.)
3 000 5/30/086/27/087/25/088/22/089/19/0810/17 /0811/14/0812/12/081/9/092/6/093/6/094/3 /095/1/095/29/096/26/097/24/098/21/099/1 8/0910/16/0911/13/0912/11/091/8/102/5/10 3/5/104/2/104/30/105/28/10 TMOT VolumeWeek EndingBranded COZAARG eneric Losartan32,025 245,129 % of Total (Cozaar + generic) 10 11 - - ,8 Source: Robert Kneller. Nature Reviews Drug Discovery, Modified 13 AMED 1 AMED 14 , IT VC PMDA 15 1.
4 2. 3. AI 16 Society Society Society Society Society AI 17
